Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18

WELLESLEY, MA--(Marketwired - Sep 16, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in bleeding during surgery, announces that co-founder, inventing scientist and advisor Dr. Rutledge Ellis-Behnke will present research involving AC5^™ at the 12th Annual Current Issues in Medicine, Biotech and Pharma Conference at Rensselaer Polytechnic Institute in Troy, NY on Thursday, September 18.

Dr. Ellis-Behnke's talk, titled "Molecular Medical Devices to Stabilize and Repair Tissue - Current Issues," will be held at 3:30 p.m. EDT in the Biotech Center Main Auditorium.

Dr. Raj Bawa, chair and founding organizer of the annual conference, said, "The conference will examine the entire 'product wheel' from preclinical research to product development to final market introduction." He continued, "It is unique because it not only highlights cutting‐edge current issues and technological advances in medicine, law, biotechnology, pharmaceutical sciences, engineering and biomedicine, it also addresses critical ancillary topics that relate to these fields, namely, safety and toxicity, biosimilars, business strategy, licensing and tech transfer, intellectual property, FDA regulatory issues, and governmental policy issues." 

Dr. Ellis-Behnke discovered the hemostatic and other barrier properties of self-assembling peptides that could make future surgery and interventional care both faster and safer. He proposed the development and commercialization of what became Arch Therapeutics' flagship product candidate, now known as AC5. Arch Therapeutics obtained the exclusive worldwide license on the relevant intellectual property, of which Dr. Ellis-Behnke is the lead inventor, from the Massachusetts Institute of Technology and focused on design and manufacturing at the nanoscale in order to bring AC5 closer to commercialization. He recently completed an animal study in which AC5 was agnostic to the presence of therapeutic levels of the anticoagulant heparin, commonly known as a blood thinner. A large percent of patients take blood thinners, and they are at risk of bleeding, especially during surgery. The Company believes AC5 might provide significant opportunity for these patients in need.